
Vraylar
(cariprazine) capsules
0.5mg·0.75mg·1.5mg·3mg·4.5mg·6mg
A CLINICAL OVERVIEW OF VRAYLAR®:
MANAGING DEPRESSION
IN MDD (ADJUNCTIVE) & BIPOLAR I PATIENTS
Overview of major depressive disorder and BP-I depression, including the potential impact on patients, similarity in presentation of depressive symptoms, and the hypothesized role select brain receptors are believed to play in both disorders. Presentation will include a clinical overview of VRAYLAR for adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) and for the treatment of depressive episodes associated with bipolar I disorder in adults.
Thursday, August 13, 2026
at 6:00 PM CT
Sullivan's Steakhouse
4501 West 119th Street
Leawood, KS 66209
PRESENTED BY:
Pamela Sisk, APRN
Leawood, KS
RSVP AT: http://www.vraylarlive.com/register/248922
If you cannot join us for this event, please go to https://www.vraylarlive.com to register for another event in your area. To register via phone, please call 888-335-8430.
Please reference Meeting ID 248922. For questions contact your AbbVie Representative Amanda Lambright Phone: 9134612088
OR SCAN HERE TO REGISTER
INDICATIONS AND USAGE
VRAYLAR (cariprazine) is indicated for adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults, for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults, for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adult and pediatric patients 10 years of age and older, and for the treatment of schizophrenia in adult and pediatric patients 13 years of age and older.
IMPORTANT SAFETY INFORMATION
WARNINGS: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS
• Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. VRAYLAR is not approved for treatment of patients with dementia-related psychosis.
IMPORTANT SAFETY INFORMATION (continued)
• Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors.
Contraindication: VRAYLAR is contraindicated in patients with known hypersensitivity. Reactions have included rash, pruritus, urticaria, and reactions suggestive of angioedema.
Cerebrovascular Adverse Reactions, Including Stroke: In clinical trials with antipsychotic drugs, elderly patients with dementia had a higher incidence of cerebrovascular adverse reactions, including fatalities, vs placebo. VRAYLAR is not approved for the treatment of patients with dementia-related psychosis.
Please see additional Important Safety Information on next page.
Please also see accompanying full Prescribing Information, including Boxed Warnings, or visit https://www.rxabbvie.com/pdf/vraylar_pi.pdf.